A phase I study of SLN 501 for Complement-Mediated Diseases
Latest Information Update: 18 Mar 2024
At a glance
- Drugs SLN 501 (Primary)
- Indications Immunological disorders
- Focus Adverse reactions
- 13 Mar 2024 According to a Silence Therapeutics media release, In March 2024, Mallinckrodt notified Silence that they will not pursue further development of SLN501 following the completion of the phase 1 clinical trial. This will conclude all activities and commitments under the collaboration agreement.
- 13 Mar 2024 Status changed to completed , according to a Silence Therapeutics media release
- 23 Mar 2022 According to a Silence Therapeutics media release, the Mallinckrodt plc has filed a clinical trial application (CTA) for SLN501, an siRNA targeting the complement C3 protein, triggering a $3 million milestone payment to Silence. Silence is responsible for executing the development program for SLN501 until the end of phase I, after which Mallinckrodt will assume responsibility for clinical development and global commercialization.